An update on the use of stem cell therapy for erectile dysfunction

The objective of this systematic review was to analyze animal and human trial data to better understand the efficacy of stem cell therapy (SCT) for erectile dysfunction (ED) and the obstacles that may encounter its application in this field. We searched electronic databases, including PubMed and Scopus, for published studies with the Medical Subject Heading (MeSH) of "erectile dysfunction" (AND) "stem cell therapy" (OR) "erectile dysfunction' (AND) "clinical trial of stem cell therapy" (OR) "stem cell therapy" (AND) "sexual dysfunction". The search was limited to English-language journals and full papers only. The initial search resulted in 450 articles, of which 90 relevant to our aims were included in the analysis. ED is a multifactorial disease. Current treatment options rely on pharmacotherapy as well as surgical options. Patients may have side effects or unsatisfactory results following the use of these treatment options. SCT may restore pathophysiological changes leading to ED rather than treating the symptoms. It has been evaluated in animal models and shown promising results in humans. Results confirm that SCT does improve erectile function in animals with different types of SC use. In humans, evidence showed promising results, but the trials were heterogeneous and limited mainly by a lack of randomization and the small sample size. Many challenges could limit future research in this field, including ethical dilemmas, regulation, patient recruitment, the cost of therapy, and the lack of a standardized SCT regimen. Repairing and possibly replacing diseased cells, tissues, or organs and eventually retrieving normal function should always be the goals of any therapy, and this can only be guaranteed by SCT. SCT is a potential and successful treatment for ED, particularly in patients who are resistant to classic therapy. SCT may promote nerve regeneration and vascular cell regeneration, not only symptomatic treatment.